➡️@VericiDx Investor Presentation
#VRCI will provide a live presentation via @InvestorMeetCo
🕟4:30pm
📅Tues 27 Oct '26
🗣️Sara Barrington, CEO, will discuss the recent fundraise, which is anticipated to provide sufficient runway to achieve cash-flow breakeven by the end of '27
Investors can sign up to Investor Meet Company for free and add to meet Verici Dx via: investormeetcompany.com/veri…
✅@onehealthgroup Trading Update
🚀H1 27 Revenue & EBITDA significantly ahead of prior year
📈Strong growth across all KPIs
🏗️Construction of 1st hub progressing well - shell now weather-tight & expected to open in Spring '27
➡️#OHGR will announce H1 27 results in late Nov '26
✅@hargreaves_plc (AIM: #HSP) announces that they have been awarded a 15-year contract providing logistics services to the UK Deposit Return Scheme
londonstockexchange.com/en/n…
Read more below ⤵️
✅@Renalytix - US Kidney Care National Plan reinforces kidneyintelX.dkd opportunity
🚀 Marks a shift in US policy from managing kidney failure towards preventing it
➡️ Aligns directly with kidneyintelX.dkd, #RENX's FDA-authorized and Medicare-reimbursed prognostic blood test
🔑 Key themes of the Plan and their relevance:
✅ Prevention is now the stated federal priority
✅ kidneyintelX.dkd’s patient population is identified as the problem to solve
✅ Expanding early detection
✅ Implementing precision-based care
Read here: hhs.gov/press-room/hhs-launc…
➡️@VericiDx (AIM: #VRCI) welcomes the Launch of US Kidney Care National Plan
The 2026 Kidney Care National Plan centres on 3 priorities:
✅ Prevent Kidney Failure
🩸 Improve Dialysis Care and Expand Patient Choice
🚀 Reform Transplantation
Read here: hhs.gov/press-room/hhs-launc…
Replying to @FsnAntibodies
@FsnAntibodies plc (AIM: #FAB) - Contract Win
✅ New project covering the transient gene expression of a client’s lead antibody and a subsequent cryogenic electron microscopy study under an existing master services agreement with a global pharmaceutical company
➡️@Parsortix (AIM: #CLBX) - MSA with a Swiss biotech company
✒️Entered into MSA & a Statement of Work for a Radio-Pharmaceutical Clinical Study
✅In 2025, the market size of radioligand-therapy market had a value of ~ $3.0b, increasing to between $10.9b and $15.9b by 2035
⬆️Greater automation reduces delivery time and increases capacity,
👏The platform is currently being trialled by several customers across Chile, Singapore, the United States and the United Kingdom ahead of the planned commercial launch in December.
RNS -
londonstockexchange.com/news…
Harin Vaghela, Chief Product Officer, provides an overview of the new Invention Evaluator platform -
youtube.com/embed/cF1PR2mpbS…










